ClinicalTrials.gg
WithdrawnNCT03770299CheckMate 9TNUpdated Mar 24, 2022

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

A Phase 2 interventional study of Nivolumab and Vinorelbine in Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma and Circulating Tumor DNA, sponsored by Bristol-Myers Squibb. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-24.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
114th of 120
0 · median 66
Started
2021
with 7 others
Phase 2
66 of 120
16 open now
Registered
71st of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 114th largest by enrollment, is one of 8 that started in 2021, is one of 66 in phase 2, and was the 71st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Non-Small-Cell Lung Carcinoma
  • Circulating Tumor DNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspected or confirmed Stage IIA to IIIB NSCLC with disease that is considered resectable
  • Must be deemed eligible for complete resection and must agree to undergo standard of care surgery for complete resection of NSCLC
  • Treatment naive (no previous systemic treatment)

Inclusion Criteria prior to Treatment Randomization:

  • Must have undergone complete surgical resection of their Stage IIA to IIIB NSCLC
  • Must have adequately recovered from surgery at the time of randomization
  • Minimal residual disease (MRD) positive results as detected by ctDNA

Exclusion criteria

Exclusion Criteria prior to Surgery:

  • Participants with known EGFR mutations which are sensitive to available targeted inhibitor therapy (Prior to treatment randomization in select sites)
  • Active, known or suspected disease
  • Participants with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of randomization

Exclusion Criteria prior to Treatment Randomization:

  • Must continue to meet Exclusion Criteria prior to Surgery
  • Must have no evidence of disease after surgery
  • Received a live/attenuated vaccine within 30 days of first treatment

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A

    Nivolumab + SOC (chemotherapy in eligible participants or observation)

    Biological: Nivolumab · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Docetaxel · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Other: Observation

  • Active comparator
    Arm B

    SOC (chemotherapy in eligible participants or observation)

    Drug: Vinorelbine · Drug: Gemcitabine · Drug: Docetaxel · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Other: Observation

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • OtherObservation

    Observation by the investigator

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    Time frame: Approximately 24 months

Secondary outcomes

  1. Circulating tumor DNA (ctDNA) response rate

    Time frame: Approximately 36 months

  2. ctDNA duration of response (DOR)

    Time frame: Approximately 36 months

  3. ctDNA time to response (TTR)

    Time frame: Approximately 36 months

  4. Incidence of adverse events (AEs)

    Time frame: Approximately 36 months

  5. Incidence of serious adverse events (SAEs)

    Time frame: Approximately 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2021; primary completion for Mar 2023, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Dec 10, 2018
StartEst.
Jan 15, 2021
Primary completionEst.
Mar 14, 2023
CompletionEst.
Mar 14, 2024
Last update
Mar 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03770299
Responsible party
Sponsor
First posted
Dec 10, 2018
Start date
Jan 15, 2021 (estimated)
Primary completion
Mar 14, 2023 (estimated)
Completion
Mar 14, 2024 (estimated)
Last update
Mar 24, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion